Management of mineral and bone disorder in chronic kidney disease: Quo vadis?

Therapeutic Apheresis and Dialysis

Volumn 13, Issue SUPPL. 1, 2009, Pages

  Nakai, Kentaro ^a   Komaba, Hirotaka ^a   Fukagawa, Masafumi ^a,b  

^a KOBE UNIVERSITY   (Japan)

^b TOKAI UNIVERSITY   (Japan)

Author keywords

Chronic kidney disease mineral and bone disorder (CKD MBD); Cinacalcet hydrochloride; Parathyroid hormone; Secondary hyperparathyroidism; Vitamin D analog

Indexed keywords

CALCIMIMETIC AGENT; CALCIUM; CINACALCET; DOXERCALCIFEROL; PARATHYROID HORMONE; PARICALCITOL; PHOSPHORUS; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D DERIVATIVE; VITAMIN D STEROL;

BLOOD VESSEL CALCIFICATION; CALCIUM ABSORPTION; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; HEMODIALYSIS PATIENT; HORMONE INHIBITION; HUMAN; INTESTINE ABSORPTION; LOW DRUG DOSE; MORBIDITY; MORTALITY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RECURRENT DISEASE; RENAL OSTEODYSTROPHY; REVIEW; SECONDARY HYPERPARATHYROIDISM; TREATMENT OUTCOME;

BONE DISEASES, METABOLIC; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; NAPHTHALENES; PARATHYROID HORMONE; RENAL DIALYSIS; VITAMIN D; VITAMINS;

EID: 70349338532     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2009.00767.x     Document Type: Review

References (45)

1. Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004 350 : 1516 1525.
2. Covic A, Kothawala P, Bernal M et al. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant 2009 24 : 1506 1523.
3. Moe S, Drueke T, Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006 69 : 1945 1953.
4. Guideline Working Group, Japanese Society for Dialysis Therapy. Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial 2008 12 : 514 525.
5. Nakai S, Akiba T, Kazama J et al. Effects of serum calcium, phosphorous, and intact parathyroid hormone levels on survival in chronic hemodialysis patients in Japan. Ther Apher Dial 2008 12 : 49 54.
6. Kimata N, Albert JM, Akiba T et al. Association of mineral metabolism factors with all-cause and cardiovascular mortality in hemodialysis patients: the Japan dialysis outcomes and practice patterns study. Hemodial Int. 2007 11 : 340 348.
7. Kimata N, Miwa N, Otsubo S et al. Achievement of the Japanese Society for Dialysis Therapy guideline targets for mineral metabolism measures: one Japanese University center result. Ther Apher Dial 2007 11 (Suppl 1 S62 6.
8. Komaba H, Igaki N, Takashima M et al. Calcium, phosphorus, cardiovascular events and all-cause mortality in hemodialysis patients: a single-center retrospective cohort study to reassess the validity of the Japanese Society for Dialysis Therapy guidelines. Ther Apher Dial 2008 12 : 42 8.
9. Fukagawa M, Yumita S, Akizawa T et al. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant 2008 23 : 328 335.
10. Komaba H, Fukagawa M. Impact of cinacalcet hydrochloride on the achievement of the Japanese Society for Dialysis Therapy (JSDT) guideline targets: a post-hoc analysis of the KRN1493 study. Ther Apher Dial 2008 12 (Suppl 1 S44 9.
11. Nemeth EF, Steffey ME, Hammerland LG et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 1998 95 : 4040 4045.
12. Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004 350 : 1516 1525.
13. Lindberg JS, Culleton B, Wong G et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study. J Am Soc Nephrol 2005 16 : 800 807.
14. Palmer SC, McGregor DO, Macaskill P et al. Meta-analysis: Vitamin D compounds in chronic kidney disease. Ann Intern Med 2007 147 : 840 853.
15. Al-Badr W, Martin KJ. Vitamin D and kidney disease. Clin J Am Soc Nephrol 2008 3 : 1555 1560.
16. Strippoli GF, Palmer S, Tong A et al. Meta-analysis of biochemical and patient-level effects of calcimimetic therapy. Am J Kidney Dis 2006 47 : 715 726.
17. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003 42 (Suppl 3 S1 202.
18. Torres A, Lorenzo V, Hernandez D et al. Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. Kidney Int 1995 47 : 1434 1442.
19. Messa P, Macario F, Yaqoob M et al. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 2008 3 : 36 45.
20. Fishbane S, Shapiro WB, Corry DB et al. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin J Am Soc Nephrol 2008 3 : 1718 1725.
21. St Peter WL, Li Q, Liu J et al. Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006. Clin J Am Soc Nephrol 2009 4 : 354 360.
22. Teng M, Wolf M, Lowrie E et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003 349 : 446 456. (Pubitemid 36910023)
23. Shoji T, Shinohara K, Kimoto E et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 2004 19 : 179 184.
24. Teng M, Wolf M, Ofsthun MN et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005 16 : 1115 1125.
25. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006 70 : 771 780.
26. Tentori F, Hunt WC, Stidley CA et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006 70 : 1858 1865.
27. Serra AL, Savoca R, Huber AR et al. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients. Nephrol Dial Transplant 2007 22 : 577 583.
28. Eriguchi R, Umakoshi J, Tominaga Y et al. Successful treatment of inoperable recurrent secondary hyperparathyroidism with cinacalcet HCl. NDT Plus 2008 1 : 218 220.
29. Fukagawa M, Kitaoka M, Yi H et al. Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patient. Nephron 1994 68 : 221 228.
30. Okuno S, Ishimura E, Kitatani K et al. Relationship between parathyroid gland size and responsiveness to maxacalcitol therapy in patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2003 18 : 2613 2621.
31. Tominaga Y, Inaguma D, Matsuoka S et al. Is the volume of the parathyroid gland a predictor of maxacalcitol response in advanced secondary hyperparathyroidism? Ther Apher Dial 2006 10 : 198 204.
32. Wada M, Furuya Y, Sakiyama J et al. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest 1997 100 : 2977 2983.
33. Colloton M, Shatzen E, Miller G et al. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 2005 67 : 467 476.
34. Mizobuchi M, Hatamura I, Ogata H et al. Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency. J Am Soc Nephrol 2004 15 : 2579 2587.
35. Rodriguez M, Almaden Y, Canadillas S et al. The calcimimetic R-568 increases vitamin D receptor expression in rat parathyroid glands. Am J Physiol Renal Physiol 2007 292 : F1390 5.
36. Mizobuchi M, Ogata H, Hatamura I et al. Activation of calcium-sensing receptor accelerates apoptosis in hyperplastic parathyroid cells. Biochem Biophys Res Commun 2007 362 : 11 16.
37. Lomonte C, Vernaglione L, Chimienti D et al. Does vitamin D receptor and calcium receptor activation therapy play a role in the histopathologic alterations of parathyroid glands in refractory uremic hyperparathyroidism? Clin J Am Soc Nephrol 2008 3 : 794 799.
38. Tanaka M, Nakanishi S, Komaba H et al. Association between long-term efficacy of cinacalcet and parathyroid gland volume in haemodialysis patients with secondary hyperparathyroidism. NDT Plus 2008 1 : iii49 53.
39. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005 68 : 1793 1800.
40. Chertow GM, Pupim LB, Block GA et al. Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol 2007 2 : 898 905.
41. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998 339 : 584 590.
42. Eknoyan G, Beck GJ, Cheung AK et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002 347 : 2010 2019.
43. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005 353 : 238 248. (Pubitemid 41058323)
44. Suki WN, Zabaneh R, Cangiano JL et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007 72 : 1130 1137.
45. Komaba H, Tanaka M, Fukagawa M. Treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Intern Med 2008 47 : 989 994.